A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Summary

The purpose of this study is to see whether combination of low dose lenalidomide(10mg)+ dexamethasone is equally effective in treating relapsed/refractory myeloma in the group of elderly patients and other patients at risk of myelosuppression, whilst producing less side effects, especially myelosuppression compared to the higher dose of lenalidomide of 25mg used in the MM-009 and MM-010 trials.

Timeline

Start

2007-06

Primary completion

2010-08

Completion

2014-02

Publications

• Cooke RE, Gherardin NA, Harrison SJ, Quach H, Godfrey DI, Prince M, Koldej R, Ritchie DS. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. J Transl Med. 2016 Sep 6;14(1):259. doi: 10.1186/s12967-016-0994-6.

Drugs

Indications